MCMedicalCodingSoftware
Free trial
XW03372

XW03372: Introduction of Inactivated Coagulation Factor Xa into Peripheral Vein, Percutaneous Approach, New Technology Group 2

Billable / specific codeICD-10-PCS

CMS abbreviated title: Introduce Coag Factor Xa in Periph Vein, Perc, New Tech 2

How XW03372 is built

Every ICD-10-PCS code is seven independent character positions. Each one is a separate decision, and the meaning of a character depends on the positions before it.

  1. XSectionNew Technology: What family of procedure this is
  2. WBody systemWhich system it acts on
  3. 0Root operationThe objective: the verb of the procedure
  4. 3Body partThe specific site
  5. 3ApproachHow the site was reached
  6. 7DeviceWhat was left in place, if anything
  7. 2QualifierA further distinction where one applies

Codes near XW03372

In CMS’s own ordering, which groups codes that differ by only the last character or two, usually the approach, device or qualifier.

  • XW0331BIntroduction of Anitocabtagene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 11
  • XW0333AIntroduction of Bentracimab, Ticagrelor Reversal Agent into Peripheral Vein, Percutaneous Approach, New Technology Group 10
  • XW0334AIntroduction of Cefepime-taniborbactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 10
  • XW03357Introduction of Narsoplimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 7
  • XW03358Introduction of Mosunetuzumab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 8
  • XW0335AIntroduction of Ceftobiprole Medocaril Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 10
  • XW03368Introduction of Afamitresgene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 8
  • XW0336CIntroduction of Landiolol Antiarrhythmic into Peripheral Vein, Percutaneous Approach, New Technology Group 12
  • XW03372Introduction of Inactivated Coagulation Factor Xa into Peripheral Vein, Percutaneous Approach, New Technology Group 2
  • XW03378Introduction of Tabelecleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 8
  • XW0337CIntroduction of Zimislecel Allogeneic Stem Cell-Derived Islet Cell Therapy into Peripheral Vein, Percutaneous Approach, New Technology Group 12
  • XW03388Introduction of Treosulfan into Peripheral Vein, Percutaneous Approach, New Technology Group 8
  • XW0338AIntroduction of Obecabtagene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 10
  • XW03396Introduction of Ceftolozane/Tazobactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 6
  • XW03398Introduction of Inebilizumab-cdon into Peripheral Vein, Percutaneous Approach, New Technology Group 8
  • XW0339AIntroduction of Odronextamab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 10
  • XW033A7Introduction of Ciltacabtagene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 7
ICD-10-PCSFY2027